BIO Reveals Program for 2013 BIO Convention in China
3^rd Annual BIO China Will Provide Global Look at Innovation and Investment
Opportunities in China
BIO Convention in China 2013 BIO Convention in China 2013:Biotechnology
Industry Organization (BIO)
WASHINGTON -- October 31, 2013
The Biotechnology Industry Organization (BIO) today announced panel sessions
for the 3^rd annual BIO Convention in China to be held November 11-13, 2013 in
Beijing. The program will feature science-focused sessions such as vaccine
development, China’s unmet medical needs and the research and development of
orphan drugs to treat rare diseases in China, as well as business-focused
sessions exploring China’s private health care industry, early-stage VC
funding in China, and partnering models between Chinese and Western companies.
Convention programming and exhibition will take place November 12-13.
“China has the potential to build a world-class innovative biologics sector,"
said Joseph Damond, senior vice president of international affairs at
BIO.“This year’s BIO China program helps support that ambition by bringing
together western and Chinese life sciences companies as well as business
leaders, government officials and other industry representatives for learning
and deal-making opportunities.”
Three can’t miss panels include:
*Company Partnerships in Vaccine Developments in China
China and its neighboring countries represent a significant private sector
opportunity for new vaccines. Chinese vaccine companies, working in
partnership with other vaccine companies, are developing important
medicine that addresses the specific unmet medical needs in China and
other Asian markets. These collaborations bring novel vaccine technology
into the Chinese research institutions while offering small and large
Western vaccine companies the opportunity to bring new products to the
growing Chinese private sector. Vaccines that protect against pneumococcal
disease, HPV, influenza and RSV are in development or clinical trials. The
panelists for this topic will discuss successful partnerships designed to
solve key public health issues in China and other emerging markets.
Tuesday, November 12, 11:00 a.m. – 11:55 a.m.
Moderator: Ralf Altmeyer, PhD, Director General, Institut Pasteur of
Shanghai, Chinese Academy of Sciences
Panelists: Li Shi, CEO, Shanghai Zerun Biotech; Jean-Denis Shu, MD,
Medical Director, Sanofi Pasteur, China
*Rare Diseases in China
The establishment of China’s first national organization against rare
diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms
the country’s commitment to innovative health care research. China is
actively promoting the regulation of rare diseases and orphan drugs. This
panel will focus on the research and development of orphan drugs in China.
Tuesday, November 12, 1:30 p.m. – 2:25 p.m.
Moderator: Kewen Jin, Managing Director, Nimbus Innoworks
Panelists: Rachel Lee, China Country President, Shire; Ko-Chung Lin, PhD,
Founder & CEO, Pharmaessentia; Jerry Zeldis, PhD, Chief Executive Officer,
Celgene Global Health and Chief Medical Officer, Celgene Corporation
*Dissecting China’s Unmet Medical Needs
The prevalence of cancer, diabetes and cardiovascular diseases continue to
rise in China, primarily due to a growing aging population and
urbanization. To what extent are current standards of care falling short,
and what novel products and technologies are around the corner to fill the
void? Hear leading experts discuss these questions, and learn how the
industry is addressing unmet medical needs to improve healthcare in China.
Wednesday, November 13, 1:00 p.m. – 1:55 p.m.
Moderator: Nick Zhang, PhD, China General Manager, Senior Vice President,
Panelists: Friedhelm Blobel, PhD, President & CEO, SciClone
Pharmaceuticals; Bruno Osterwalder, MD, Senior VP, Senior Strategic
Advisor Oncology, Global Drug Development and Medical, Merck Serono;
Russell Wilson, Senior Vice President, Business Development, Novavax;
Grace Xu, VP, Product Development & Strategic Planning, Bristol-Myers
Other BIO China sessions include:
*Roadmap to Cultivate Innovative Biologics Industry in China
The bio-industry has been designated as one of China’s seven strategic
emerging industries (SEI) by the government. Within the bio-industry,
therapeutic biologics hold significant promise for China to achieve
breakthrough innovation and to address largely unmet medical needs in many
disease areas. Today, China’s therapeutic biologics industry stands at RMB
18 billion, representing less than 2 percent of the global total. This
panel will explore the steps that may be taken by the government and
industry to develop a world-class innovative biologics sector in China.
*State of Capital Markets in US
With capital markets opening up, 2013 saw 39 (and counting) new biotech
IPOs – many of which are staying strong even after their initial debut.
Will this excitement continue onto 2014 and translate into new
opportunities for China? This panel will explore the state of the capital
markets in China in comparison to the exciting new developments in the
U.S. through the prism of biotech insiders, as well as assess the current
and future attractiveness of local IPOs, providing a global and insightful
perspective to both companies and investors.
*China’s Private Health Care Industry
China has committed to making private healthcare a larger part of the
overall ecosystem, aiming for 20% of beds and 20% of spending to be
conducted through private institutions by 2020. This panel will explore
the opportunities and challenges for private insurers, providers,
pharmaceutical companies and device manufacturers looking to capitalize on
the rapidly growth in private healthcare.
*Early-stage VC funding in China
While there are still only a few early-stage bio-investors in China, the
number of funding sources is starting to increase, kick-starting Chinese
biotech. Where will this diversity of investments take China’s biotech
industry in the coming years? Hear investors assess the current state of
early-stage VC funding in China and the long-term outlook for biotech.
*Case Studies: Partnering Models between Chinese & Western Companies
Through in-licensing, out-licensing, JV/Alliances and M&A, an increasing
number of Chinese and Western companies are collaborating to bring
therapeutics to the market. This session will highlight recent deals from
2013 to discuss their respective deal structures, what companies need to
consider to produce the most fruitful partnerships, and where they see
China and Western collaborations moving in the future.
In addition to panel sessions, BIO China will host company presentations,
partnering meetings and networking opportunities. Keynote speakers will
*Governor Jay Inslee, Washington State
*Gary F. Locke, Ambassador of the United States of America to the People’s
Republic of China
*Bian Zhenjia, Assistant Minister, CFDA
*Zhao Yajun, Director General, China Center for Pharmaceutical Exchange
*James C. Greenwood, President and CEO, Biotechnology Industry Organization
BIO brings to China more than 17 years of experience in organizing
international conferences for the biotech industry, including the BIO
International Convention, the world’s largest annual biotech conference. BIO
is renowned for its successful business development, partnering and investor
meetings in North America, Europe and Asia. Partnering at this conference will
be powered by BIO One-on-One Partnering™, an interactive environment to
intelligently search, contact and schedule private meetings with potential
partners and investors.
For more information on the BIO Convention in China, please visit here.
BIO represents more than 1,100 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO members are involved in the research
and development of innovative healthcare, agricultural, industrial and
environmental biotechnology products. BIO also produces the BIO International
Convention, the world’s largest gathering of the biotechnology industry, along
with industry-leading investor and partnering meetings held around the world.
BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling
“innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
BIO IPCC Conference
November 6-8, 2013
BIO Convention in China
November 11-13, 2013
Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 8-11, 2013
San Diego, CA
BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY
BIO Asia International Conference
April 8-9, 2014
World Congress on Industrial Biotechnology
May 12-15, 2014
BIO International Convention
June 23-26, 2014
San Diego, CA
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD
Biotechnology Industry Organization
Contact in China:
Amber He, +86 10 8443 9471
Contact in U.S.:
Daniel Seaton, 202-962-5207
Press spacebar to pause and continue. Press esc to stop.